Richard Carvajal

Richard Carvajal at Columbia has contributed to uveal melanoma research — a rare and distinct melanoma type arising from the eye with GNAQ/GNA11 mutations (not BRAF) and high rates of liver metastases. He led clinical development of tebentafusp (a bispecific T cell receptor/anti-CD3 fusion) which demonstrated overall survival benefit in uveal melanoma — the first agent to do so in this disease — establishing a new treatment paradigm for this resistant cancer.